National trends in radiation dose escalation for glioblastoma
Rodney E. Wegner, Stephen Abel, Zachary D. Horne, Shaakir Hasan, Vivek Verma, Tulika Ranjan, Richard W. Williamson, Stephen M. Karlovits
Radiat Oncol J. 2019;37(1):13-21.   Published online 2019 Mar 31     DOI: https://doi.org/10.3857/roj.2019.00017
Citations to this article as recorded by Crossref logo
Targeting Glioma Stem Cells
Yagmur Muftuoglu, Frank Pajonk
Neurosurgery Clinics of North America.2021; 32(2): 283.     CrossRef
Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2)
Marica Ferro, Milena Ferro, Gabriella Macchia, Savino Cilla, Milly Buwenge, Alessia Re, Carmela Romano, Mariangela Boccardi, Vincenzo Picardi, Silvia Cammelli, Eleonora Cucci, Samantha Mignogna, Liberato Di Lullo, Vincenzo Valentini, Alessio Giuseppe Morg
Frontiers in Oncology.2021;[Epub]     CrossRef
Novel Treatment for Glioblastoma Delivered by a Radiation Responsive and Radiopaque Hydrogel
Mathilde Bouché, Yuxi C. Dong, Saad Sheikh, Kimberly Taing, Deeksha Saxena, Jessica C. Hsu, Minna H. Chen, Ryan D. Salinas, Hongjun Song, Jason A. Burdick, Jay Dorsey, David P. Cormode
ACS Biomaterials Science & Engineering.2021; 7(7): 3209.     CrossRef
Peritumoral edema status of glioblastoma identifies patients reaching long-term disease control with specific progression patterns after tumor resection and high-dose proton boost
Hsiang-Kuang Tony Liang, Masashi Mizumoto, Eiichi Ishikawa, Masahide Matsuda, Keiichi Tanaka, Hidehiro Kohzuki, Haruko Numajiri, Yoshiko Oshiro, Toshiyuki Okumura, Akira Matsumura, Hideyuki Sakurai
Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3503.     CrossRef
Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013
Jad Zreik, F. M. Moinuddin, Yagiz U. Yolcu, Mohammed Ali Alvi, Kaisorn L. Chaichana, Alfredo Quinones-Hinojosa, Mohamad Bydon
Journal of Neuro-Oncology.2020; 148(1): 69.     CrossRef
Survival of glioblastoma treated with a moderately escalated radiation dose—Results of a retrospective analysis
Li-Tsun Shieh, How-Ran Guo, Chung-Han Ho, Li-Ching Lin, Chin-Hong Chang, Sheng-Yow Ho, Stephen Chun
PLOS ONE.2020; 15(5): e0233188.     CrossRef
Advances in drug delivery technology for the treatment of glioblastoma multiforme
Gi Doo Cha, Taegyu Kang, Seungmin Baik, Dokyoon Kim, Seung Hong Choi, Taeghwan Hyeon, Dae-Hyeong Kim
Journal of Controlled Release.2020; 328: 350.     CrossRef
Trimodality therapy for atypical teratoid/rhabdoid tumor is associated with improved overall survival: A surveillance, epidemiology, and end results analysis
Thomas J. Quinn, Muayad F. Almahariq, Zaid A. Siddiqui, Andrew B. Thompson, Daniel A. Hamstra, Peyman Kabolizadeh, Kate L. Gowans, Peter Y. Chen
Pediatric Blood & Cancer.2019;[Epub]     CrossRef
Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy
Danielle Cicka, Charles Lester Ford, Erica Templin, Zachary Pitts, Saumya Gurbani, Bree Eaton, Lindsey Lowder, Jeffrey Olson, Brent D Weinberg, Hyunsuk Shim, Soma Sengupta
Oxford Medical Case Reports.2019;[Epub]     CrossRef
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
Wolfgang Wick, Andriy Krendyukov, Klaus Junge, Thomas Höger, Harald Fricke
Journal of Neuro-Oncology.2019; 145(3): 531.     CrossRef